NCT03471364View on ClinicalTrials.gov

Ketoconazole in Treating Participants With Ongoing EGFR Inhibitor-Induced Rash

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

58

Participants

Timeline

Start Date

September 25, 2018

Primary Completion Date

September 15, 2024

Study Completion Date

September 15, 2024

Conditions
Malignant Neoplasm
Interventions
DRUG

Ketoconazole

Applied topically

OTHER

Laboratory Biomarker Analysis

Correlative studies

OTHER

Placebo Administration

Applied topically

OTHER

Quality-of-Life Assessment

Ancillary studies

OTHER

Questionnaire Administration

Ancillary studies

Trial Locations (6)

14642

University of Rochester, Rochester

55101

Regions Hospital, Saint Paul

55426

Park Nicollet Frauenshuh Cancer Center, Saint Louis Park

55905

Mayo Clinic in Rochester, Rochester

61801

Carle Cancer Center, Urbana

61832

Carle on Vermilion, Danville

Sponsors

Lead Sponsor

Mayo Clinic
All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Mayo Clinic

OTHER